Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Burman, Joachim  [Clear All Filters]
2024
Kalincik T, Sharmin S, Roos I, Massey J, Sutton I, Withers B, Freedman MS, Atkins H, Krasulova E, Havrdova EKubala, et al. Effectiveness of autologous haematopoietic stem cell transplantation versus natalizumab in progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2024.
Tolf A, Gauffin H, Burman J, Landtblom A-M, Flensner G. Experiences of being treated with autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: A qualitative interview study. PLoS One. 2024;19(2):e0297573.
Greco R, Alexander T, Del Papa N, Müller F, Saccardi R, Sanchez-Guijo F, Schett G, Sharrack B, Snowden JA, Tarte K, et al. Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee. EClinicalMedicine. 2024;69:102476.
2023
Zafeiri L, Åkerfeldt T, Tolf A, Carlson K, Skalkidou A, Burman J. Anti-Müllerian hormone and pregnancy after autologous hematopoietic stem cell transplantation for multiple sclerosis. PLoS One. 2023;18(4):e0284288.
Vaivade A, Wiberg A, Khoonsari PEmami, Carlsson H, Herman S, Al-Grety A, Freyhult E, Olsson-Strömberg U, Burman J, Kultima K. Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of relapsing-remitting multiple sclerosis patients. Lipids Health Dis. 2023;22(1):97.
Kalincik T, Sharmin S, Roos I, Freedman MS, Atkins H, Burman J, Massey J, Sutton I, Withers B, Macdonell R, et al. Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis. JAMA Neurol. 2023;80(7):702-713.
Lundblad K, Zjukovskaja C, Larsson A, Cherif H, Kultima K, Burman J. CSF Concentrations of CXCL13 and sCD27 Before and After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2023;10(5).
2022
Zjukovskaja C, Larsson A, Cherif H, Kultima K, Burman J. Biomarkers of demyelination and axonal damage are decreased after autologous hematopoietic stem cell transplantation for multiple sclerosis. Mult Scler Relat Disord. 2022;68:104210.
2019
Burt RK, Balabanov R, Burman J, Sharrack B, Snowden JA, Oliveira MCarolina, Fagius J, Rose J, Nelson F, Barreira AAntunes, et al. Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. JAMA. 2019;321(2):165-174.
Wiberg A, Olsson-Strömberg U, Herman S, Kultima K, Burman J. Profound but transient changes in the inflammatory milieu of the blood during autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019.
2015
Burt RK, Balabanov R, Han X, Sharrack B, Morgan A, Quigley K, Yaung K, Helenowski IB, Jovanovic B, Spahovic D, et al. Association of Nonmyeloablative Hematopoietic Stem Cell Transplantation With Neurological Disability in Patients With Relapsing-Remitting Multiple Sclerosis. JAMA. 2015;313(3):275-284.
2013
Burman J, Fransson M, Tötterman TH, Fagius J, Mangsbo SM, Loskog ASi. T cell responses after hematopoietic stem cell transplantation for aggressive relapsing-remitting multiple sclerosis. Immunology. 2013.